Xeris Biopharma Holdings, Inc.

2.49 USD
-0.05 (-1.97%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Xeris Biopharma Holdings, Inc. stock is up 18.01% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 42.86% of the previous 6 July’s closed higher than June.

About Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc. engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; Keveyis, a therapy for the. treatment of hyperkalemic, hypokalemic. and related variants of primary periodic paralysis.